THE PANDEMIC has caused a shift in how drug firms are viewed: their capacity for big-money innovation will give them immunity in the crisis. Widespread home working will have broad consequences, from commercial-property values to urban demographics. And a seemingly innocuous Hong Kong history exam is a window into the territory’s increasingly fraught politics. Runtime: 20 min
Listen on: Apple Podcasts | Spotify | Google | Stitcher | TuneIn
For full access to print, digital and audio editions of The Economist, subscribe here: www.economist.com/radiooffer
